The new facility will allow Astellas to expand its capacity and capabilities for aseptic drug products. Credit: JHVEPhoto / Shutterstock.com.

Astellas Pharma is submitting a planning application for the construction of a new drug production facility in Tralee, County Kerry, Ireland.

To be based on the Industrial Development Authority’s greenfield site in Kerry Technology Park, the new facility will involve an investment of €330m.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will allow the company to expand its capacity and capabilities for aseptic drug products.

It will also bolster stable production for supply worldwide and expedite the development and commercialisation of new antibody drugs and other products.

To be constructed on a 44.7-acre site, the three-storey building will feature a total floor area of 17,000m² and a footprint of 7,300m².

See Also:

Construction is set to start in 2024, with the site operational by 2028.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new facility will align with the company’s commitment to sustainability, integrating national and international energy and environmental design standards.

The project aims to decrease water usage by 50%, lower operational energy intensity by one-third and achieve zero waste sent to landfill.

Astellas chief manufacturing officer Hideki Shima stated: “Astellas is developing innovative drugs and technologies based on our Focus Area research and development approach, placing patients at the forefront of everything we do.

“With the new facility, Astellas will aim to strengthen our in-house production capacity and capabilities and ensure a stable supply of high-quality Astellas medicines to patients around the world.”